Who
Maha Radhakrishnan
Director
Company insider
Files Form 4 as: Director, Candel Therapeutics; Director, Entrada Therapeutics; Director, Alto Neuroscience.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 8 Mar 2024
- Last trade
- 23 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jun 2026filed 24 Jun 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 23 Jun 2026filed 24 Jun 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,480 at $0.00 | filing |
| 1 Jun 2025filed 3 Jun 2025 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 8 Mar 2024filed 12 Mar 2024 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,574 at $0.00 | filing |
| 8 Mar 2024filed 12 Mar 2024 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | $16K1,590 at $10.21 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.